Medicaid GLP-1 Coverage by State: Table and CSV

10 of 51 Medicaid programs (50 states and DC) cover GLP-1 medicines for weight loss; 51 cover them for type 2 diabetes, usually with prior authorization. Find your state below.

States covering weight loss: 10 of 51
Source: State Medicaid drug lists, KFF

Medicaid GLP-1 coverage by state
State	Covers for weight loss	Covers for type 2 diabetes	Prior authorization	Notes
Alabama	No	Yes	Not listed	Alabama Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Alaska	No	Yes	Not listed	Weight-loss GLP-1s are not included in Alaska Medicaid coverage. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Arizona	No	Yes	Not listed	Under Arizona Medicaid, GLP-1s have no weight-loss coverage. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Arkansas	No	Yes	Not listed	Weight-loss coverage from Arkansas Medicaid does not include GLP-1s. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
California	No	Yes	Not listed	In January 2026, Medi-Cal ended coverage of GLP-1s used for weight loss. Diabetes and other approved uses remain covered.
Colorado	No	Yes	Not listed	Colorado Medicaid excludes GLP-1s from weight loss coverage Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Connecticut	No	Yes	Not listed	Connecticut Medicaid covers some older weight-loss drugs, but not GLP-1s for weight loss. GLP-1s are covered for type 2 diabetes and other approved uses.
Delaware	Yes	Yes	Yes	For obesity, Delaware Medicaid lists Foundayo, Wegovy and Zepbound among its preferred drugs. Prior authorization is required for every drug in this class.
District of Columbia	No	Yes	Not listed	DC Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Florida	No	Yes	Not listed	Florida Medicaid does not include GLP-1s in its weight-loss coverage. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Georgia	No	Yes	Not listed	Georgia Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Hawaii	No	Yes	Not listed	Hawaii Medicaid does not cover GLP-1s used for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Idaho	No	Yes	Not listed	Idaho Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Illinois	No	Yes	Not listed	Illinois Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Indiana	Not listed	Yes	Not listed	Indiana's July 30, 2026 announcement said Medicaid will cover certain GLP-1s for obesity under the federal BALANCE model. The cost is $245 per member per month. Eligibility and timing were not yet set.
Iowa	No	Yes	Not listed	Iowa Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Kansas	Yes	Yes	Yes	KanCare covers these anti-obesity GLP-1s: Foundayo, Wegovy, Zepbound, and Saxenda.
Kentucky	No	Yes	Not listed	Kentucky Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Louisiana	No	Yes	Not listed	Louisiana Medicaid does not cover GLP-1s for weight loss right now. From January 2027, a 2026 law allows eligible people to have FDA-approved obesity drugs covered.
Maine	No	Yes	Not listed	Maine Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Maryland	No	Yes	Not listed	Maryland Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Massachusetts	No	Yes	Yes	Effective July 3, 2026, MassHealth stopped covering Wegovy, Zepbound and Saxenda for weight loss. Approval may cover MASH, sleep apnea or heart-risk uses if prior authorization is obtained.
Michigan	Yes	Yes	Yes	Coverage under January 1, 2026, Michigan rules includes GLP-1s for weight loss only when a person is considered morbidly obese. That person must have tried other options first. Preferred anti-obesity drugs are among those options.
Minnesota	Yes	Yes	Yes	For weight loss, Minnesota covers Wegovy, Zepbound and Saxenda. Prior authorization is required. Your BMI must be 30 or more, or 27 or more if you have a weight-related condition.
Mississippi	Yes	Yes	Not listed	KFF reports that Mississippi Medicaid covers GLP-1s for obesity treatment.
Missouri	Yes	Yes	Yes	MO HealthNet covers GLP-1s for obesity and requires the same prior authorization form for every GLP-1 use.
Montana	No	Yes	Not listed	Montana Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Nebraska	No	Yes	Not listed	Nebraska Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Nevada	No	Yes	Not listed	Nevada Medicaid coverage does not include GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
New Hampshire	No	Yes	Not listed	In January 2026, New Hampshire Medicaid stopped covering GLP-1s for weight loss. Diabetes and other approved uses remain covered.
New Jersey	No	Yes	Not listed	New Jersey Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
New Mexico	No	Yes	Not listed	New Mexico Medicaid covers some older weight-loss drugs, but it does not cover GLP-1s for weight loss. GLP-1s are covered for type 2 diabetes and other approved uses.
New York	No	Yes	Not listed	Weight-loss GLP-1s are not included in New York Medicaid coverage. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
North Carolina	Yes	Yes	Yes	On December 12, 2025, NC Medicaid again covered weight-loss GLP-1s following a two-month gap. Wegovy is preferred, while Zepbound and Saxenda need an explanation of why Wegovy will not work.
North Dakota	No	Yes	Not listed	North Dakota Medicaid covers some older weight-loss drugs while excluding GLP-1s for weight loss. GLP-1s are covered for type 2 diabetes and other approved uses.
Ohio	No	Yes	Not listed	Ohio Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Oklahoma	No	Yes	Not listed	Oklahoma Medicaid does not provide coverage for weight-loss GLP-1s. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Oregon	No	Yes	Not listed	Oregon Medicaid excludes GLP-1s used for weight loss from its coverage. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Pennsylvania	No	Yes	Not listed	On January 1, 2026, Pennsylvania Medicaid stopped covering GLP-1s for overweight and obesity uses. Other uses are still covered with prior authorization.
Rhode Island	No	Yes	Yes	On October 1, 2026, Rhode Island Medicaid stopped covering Foundayo, Saxenda, Wegovy and Zepbound for weight loss alone. Other uses need a new prior authorization.
South Carolina	No	Yes	Not listed	In January 2026, South Carolina Medicaid stopped covering GLP-1s when they are used for weight loss, one year after the coverage was added. Diabetes use stays covered.
South Dakota	No	Yes	Not listed	South Dakota Medicaid does not cover GLP-1s for weight loss Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Tennessee	Yes	Yes	Yes	TennCare covers GLP-1 class weight management drugs with prior authorization. Beginning January 2026, first approvals last 3 months.
Texas	No	Yes	Not listed	Texas Medicaid covers some older weight-loss drugs, but does not cover GLP-1s for weight loss. GLP-1s are covered for type 2 diabetes and other approved uses.
Utah	No	Yes	Yes	A Utah pilot covered GLP-1s for weight loss for one year and ended June 30, 2026 Medicaid still covers these drugs for severe sleep apnea, heart risk and MASH. Prior authorization is required.
Vermont	No	Yes	Not listed	Vermont Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Virginia	Yes	Yes	Yes	Service authorization is required from Virginia Medicaid for weight-loss GLP-1s. You need a BMI of 40 or more. A BMI of 35 or more also qualifies if you have two chronic conditions. In either case, you must have tried a non-GLP-1 drug.
Washington	No	Yes	Not listed	Zepbound for weight loss is not covered by Apple Health. When you meet the criteria, Apple Health covers GLP-1s for diabetes and for other approved uses.
West Virginia	No	Yes	Not listed	West Virginia Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.
Wisconsin	Yes	Yes	Yes	With the July 1, 2026, Wisconsin policy change, a weight management drug class was added, and Foundayo and Zepbound were named as preferred. Approval requires prior authorization and a BMI of 30 or more, among other options.
Wyoming	No	Yes	Not listed	Wyoming Medicaid does not cover GLP-1s for weight loss. Coverage applies to GLP-1s used for type 2 diabetes, or for other approved uses.

Download Medicaid coverage by state as CSV

Sources (17)

KFF 1 2, medicaidpublications.dhss.delaware.gov, events.in.gov, kdhe.ks.gov, obesityaction.org, mass.gov, michigan.gov, mn.gov, dss.mo.gov, medicaid.ncdhhs.gov, pa.gov, eohhs.ri.gov, contenthub-aem.optumrx.com, medicaid-documents.dhhs.utah.gov, hca.wa.gov, forwardhealth.wi.gov.

Pages for each state

Other ways to pay